Cargando…
Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway
A postmenopausal patient with a diagnosis of estrogen receptor (ER) (+), progesterone receptor (PR) (+), and human epidermal growth factor receptor-2 (HER2) (-) breast cancer was reported. The patient refused surgery and was resistant to conventional chemotherapy regimens. Computed tomography and th...
Autores principales: | Shi, Yehui, Zhang, Wenwen, Ye, Yingnan, Cheng, Yanan, Han, Lei, Liu, Pengpeng, Zhao, Weipeng, Tong, Zhongsheng, Yu, Jinpu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chinese Anti-Cancer Association
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121052/ https://www.ncbi.nlm.nih.gov/pubmed/30197799 http://dx.doi.org/10.20892/j.issn.2095-3941.2017.0188 |
Ejemplares similares
-
Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway
por: Du, Liyan, et al.
Publicado: (2018) -
Everolimus‐containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study
por: Chen, Zhanhong, et al.
Publicado: (2019) -
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
por: Wheler, Jennifer J., et al.
Publicado: (2014) -
Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
por: Yim, Kein-Leong
Publicado: (2012) -
Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
por: Vandamme, Timon, et al.
Publicado: (2016)